Open Access Pub publishes peer-reviewed, free-to-read open-access articles. Showing
articles matching inhibitor — open any to read the full text,
or download the PDF or XML.
Aug 2017
David B HuangCorresponding author
Iclaprim is a novel bacterial dihydrofolate reductase inhibitor in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections and hospital acquired bacterial pneumonia caused by Gram-positve bacteria. Daptomycin, linezolid and vancomycin are commonly used an…
Jul 2017 DOI 10.14302/issn.2639-1716.jn-17-1495
Michael J GonzalezCorresponding author
Diets high in unsaturated fatty acids, especially those containing high levels of linoleic acid, e.g., corn oil, enhance mammary gland tumorigenesis in experimental animals. In contrast, diets high in long-chain polyunsaturated fatty acids such as eicosapentaenoic (EPA) and docosahexaenoic (DHA), e.…
Apr 2017 DOI 10.14302/issn.2372-6601.jhor-17-1463
Sylwia SzablewskaCorresponding author
Melanoma is considered to be a very aggressive cancer due to its rapid growth, early and multiple metastases and limited response to standard treatment. Many researchers have hypothesized that the combination of radiation therapy and immunotherapy in the treatment of melanoma primary tumors and meta…
Jun 2016 DOI 10.14302/issn.2572-5424.jgm-16-1028
Morris H BaslowCorresponding author
N-acetylaspartylglutamate (NAAG) is the highest concentration dipeptide present in brain. It is found primarily in neurons but its function is unclear. NAAG is synthesized by neurons from N-acetylaspartate and glutamate (Glu), maintained at mM concentrations and is released non-synaptically to extra…
May 2016 DOI 10.14302/issn.2470-5020.jnrt-15-908
Yasemin KayaCorresponding author
Objective: We aimed to investigate homocysteine levels and carotid intima-media thickness (CIMT) in Parkinson’s Disease (PD), to determine relationship of these parameters and as well as to determine whether CIMT in patients with PD was associated to age, disease duration, age of disease onset, stag…
Feb 2016 DOI 10.14302/issn.2574-4488.jna-15-712
Bassam BerniehCorresponding author
Background Dapagliflozin; the new oral hypoglycemic agent; is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that acts by inhibiting glucose reabsorption in the proximal tubule of the nephron. Main reported side effects are osmotic diuresis, dehydration, urinary tract and genital infections. Her…
Aug 2015 DOI 10.14302/issn.2372-6601.jhor-15-667
CL Cowan JrCorresponding author
Trichomegaly is a known adverse effect with the epidermal growth factor receptor inhibitor (EGFRI) and prostaglandin analogue drug classes. We present a chronic Latanoprost user who developed symptomatic trichomegaly subsequent to initiating an EGFRI medication and believe this case offers evidence…
Jan 2015 DOI 10.14302/issn.2471-7061.jcrc-14-394
Petros C. PapagiorgisCorresponding author
This review synthesizes evidence on NSAIDs and colorectal cancer prevention. It balances chemopreventive efficacy against gastrointestinal and cardiovascular risks, and considers selective COX‑2 inhibitors, dosing, and candidate populations for risk‑benefit.
Jan 2014 DOI 10.14302/issn.2328-0182.japst-12-183
Supriya D. MahajanCorresponding author
Gold nanorods (GNRs) are plasmonic nanostructures by virtue of their size-dependent optical properties, offer a bionanotechnology platform in areas of bioimaging, drug delivery etc for disease diagnosis, prognosis, and therapy. GNRs are more sensitive to changes in local environments, and offer stro…
Nov 2013 DOI 10.14302/issn.2328-0182.japst-13-185
WS WaringCorresponding author
Acute Medical Unit, York Hospital, York, UK
Background: Antidepressant agents are commonly implicated in drug overdose, and the toxicological profile varies between agents. Clinical data concerning overdoses are not systematically sought or evaluated in pharmacovigilance. The present study sought to examine the feasibility of collecting Emerg…
Sep 2013 DOI 10.14302/issn.2326-0793.jpgr-13-257
Kathleen O’ConnellCorresponding author
Lapatinib, a small molecule tyrosine kinase inhibitor is currently used in the treatment of HER2-positive breast cancer. The aim of this study was to further understanding of lapatinib response for the development of novel treatment lapatinib-focussed treatment strategies. HER2-overexpressing SKBR3…